Tetsuya Hosaka

Tetsuya Hosaka

Auto-generated profile, based on publicly available information

Tetsuya Hosaka

Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
THTetsuya Hosaka
Tetsuya Hosaka
FSFumitaka Suzuki
Fumitaka Suzuki
MKMasahiro Kobayashi
Masahiro Kobayashi
YSYuya Seko
Yuya Seko
YKYusuke Kawamura
Yusuke Kawamura
HKHiromitsu Kumada
Hiromitsu Kumada
Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought to reduce HCC development, but agents such as lamivudine (LAM) have a high rate of drug resistance. We compared the incidence of HCC in 472 entecavir (ETV)-treated patients and 1,143 nontreated HBV patients (control group). Propensity score matching eliminated the baseline differences, resulting in a sample size of 316 patients per cohort. The drug mutation resistance was 0.8% (4/472) in the ETV group. The cumulative HCC incidence rates at 5 years were 3.7% and 13.7% for the ETV and control groups, respectively (P < 0.001). Cox proportional hazard regression analysis, adjusted for a number of known HCC risk factors, showed that patients in the ETV group were less likely to develop HCC than those in the control group (hazard ratio: 0.37; 95% confidence interval: 0.15-0.91; P = 0.030). Both cohorts were applied in three previously reported risk scales and risk scores were generated based on age, gender, cirrhosis status, levels of alanine aminotransferase, hepatitis B e antigen, baseline HBV DNA, albumin, and bilirubin. The greatest HCC risk reduction occurred in high-risk patients who scored higher on respective risk scales. In sub analyses, we compared treatment effect between nucleos(t)ide analogs, which included matched LAM-treated patients without rescue therapy (n = 182). We found HCC suppression effect greater in ETV-treated (P < 0.001) than nonrescued LAM-treated (P = 0.019) cirrhosis patients when they were compared with the control group. Conclusion: Long-term ETV treatment may reduce the incidence of HCC in HBV-infected patients. The treatment effect was greater in patients at higher risk of HCC. (HEPATOLOGY 2013)

1 February 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
Yusuke KawamuraYusuke Kawamura
Yusuke Kawamura
YAYasuji Arase
Yasuji Arase
KIKenji Ikeda
Kenji Ikeda
YSYuya Seko
Yuya Seko
NINorihiro Imai
Norihiro Imai
HKHiromitsu Kumada
Hiromitsu Kumada
The aim of this study was to determine the incidence and risk factors of hepatocellular carcinoma (HCC), and to elucidate the utility of two non-invasive predictive procedures for liver fibrosis: the aspartate aminotransferase (AST) to platelet ratio index (APRI) and the BARD score (which includes the following three variables: body mass index, AST/alanine aminotransferase ratio, and diabetes) in the prediction of HCC in a large population of Japanese patients with non-alcoholic fatty liver disease (NAFLD). This was a retrospective cohort study conducted at a public hospital. Study subjects included 6,508 patients with NAFLD diagnosed by ultrasonography. The median follow-up period was 5.6 years. The primary end point was the onset of HCC. Evaluation was performed using Kaplan–Meier methodology and Cox's proportional hazards analysis. In all, 16 (0.25%) new cases with HCC were diagnosed during the study. The cumulative rates of NAFLD-related HCC were 0.02% at year 4, 0.19% at year 8, and 0.51% at year 12. The annual rate of new HCC was 0.043%. Multivariate analysis identified serum AST level ≥40 IU/L (hazard ratio (HR): 8.20; 95% confidence interval (95% CI): 2.56–26.26; P<0.001), platelet count <150 × 103/μl (HR: 7.19; 95% CI: 2.26–23.26; P=0.001), age ≥60 years (HR: 4.27; 95% CI: 1.30–14.01; P=0.017), and diabetes (HR: 3.21; 95% CI: 1.09–9.50; P=0.035) as independent risk factors for HCC. With regard to the APRI, 184 patients (2.83%) were considered to have significant fibrosis (equivalent to non-alcoholic steatohepatitis (NASH) stage 3–4). The cumulative rate of HCC was significantly higher in this group (HR: 25.03; 95% CI: 9.02–69.52; P<0.001). In contrast, regarding the BARD score, 3,841 (59%) patients were considered to have advanced fibrosis (NASH stage 3–4). However, no significant associations between the BARD score and the incidence of HCC were observed (HR: 1.16; 95% CI: 0.40–3.37; P=0.780). This retrospective study indicates that the annual incidence rate of HCC among Japanese NAFLD patients is low. Elderly NAFLD patients with diabetes, elevated serum AST, and especially thrombocytopenia (suggested to be associated with advanced liver fibrosis) should be monitored carefully during follow-up that includes using the APRI to ensure early diagnosis and treatment of HCC.

1 March 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
NANorio Akuta
Norio Akuta
FSFumitaka Suzuki
Fumitaka Suzuki
YKYusuke Kawamura
Yusuke Kawamura
HYHiromi Yatsuji
Hiromi Yatsuji
HSHitomi Sezaki
Hitomi Sezaki
HKHiromitsu Kumada
Hiromitsu Kumada

24 February 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
YAYasuji Arase
Yasuji Arase
FSFumitaka Suzuki
Fumitaka Suzuki
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
NANorio Akuta
Norio Akuta
MKMasahiro Kobayashi
Masahiro Kobayashi
HKHiromitsu Kumada
Hiromitsu Kumada
Diabetes is present in patients with chronic hepatitis C virus infection. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for type 2 diabetes after the termination of interferon therapy in Japanese patients positive for hepatitis C virus (HCV). A total of 2,842 HCV‐positive patients treated with interferon (IFN) monotherapy or combination therapy with IFN and ribavirin were enrolled. The mean observation period was 6.4 years. An overnight (12‐hour) fasting blood sample or a casual blood sample was taken for routine analyses during follow‐up. The primary goal was the onset of type 2 diabetes. Evaluation was performed by using the Kaplan‐Meier method and Cox proportional hazard analysis. Of 2,842 HCV patients, 143 patients developed type 2 diabetes. The cumulative development rate of type 2 diabetes was 3.6% at 5 years, 8.0% at 10 years, and 17.0% at 15 years. Multivariate Cox proportional hazard analysis revealed that type 2 diabetes development after the termination of IFN therapy occurred when histological staging was advanced (hazard ratio 3.30; 95% confidence interval [CI] 2.06‐5.28; P < 0.001), sustained virological response was not achieved (hazard ratio 2.73; 95% CI 1.77‐4.20; P < 0.001), the patient had pre‐diabetes (hazard ratio 2.19; 95% CI 1.43‐3.37; P < 0.001), and age was ≥50 years (hazard ratio 2.10; 95% CI 1.38‐3.18; P < 0.001). Conclusion: Our results indicate sustained virological response causes a two‐thirds reduction in the risk of type 2 diabetes development in HCV‐positive patients treated with IFN. (HEPATOLOGY 2009.)

8 July 2005 in Intervirology
Verified
Journal Article
Closed access
PDF file
NANorio Akuta
Norio Akuta
FSFumitaka Suzuki
Fumitaka Suzuki
HSHitomi Sezaki
Hitomi Sezaki
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
THTetsuya Hosaka
Tetsuya Hosaka
HKHiromitsu Kumada
Hiromitsu Kumada
Objective: Patients with high titer (≧100 kIU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve highly sustained virological response rates to combination therapy with interferon plus ribavirin. Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs. Methods: We evaluated 50 consecutive Japanese adults with high titer of HCV genotype 1b who received combination therapy for 48 weeks. We investigated the pretreatment substitution patterns in amino acids 1–191 of the core region and amino acids 2209–2248 of NS5A, and early viral kinetics. Results: Overall, a non-virological response was noted in 12 (24%) patients. Multivariate analysis identified serum albumin <3.9 g/dl, substitutions of amino acid 70 in the core region, and substitutions of amino acid 91 as independent and significant factors associated with a non-virological response. Especially, substitutions of arginine (R) by glutamine (Q) at amino acid 70, and/or leucine (L) by methionine (M) at amino acid 91 were significantly more common in NVRs. The falls in HCV-RNA levels during treatment in patients with specific substitutions in the core region were significantly less than in those without such substitutions. Conclusions: Our results suggest that serum albumin and amino acid substitution patterns in the core region in patients with high titers of HCV genotype 1b may have an effect on combination therapy in NVRs. Further large-scale studies are required to examine the role of amino acid substitutions specific to a non-virological response to combination therapy.

23 July 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
NANorio Akuta
Norio Akuta
FSFumitaka Suzuki
Fumitaka Suzuki
MHMiharu Hirakawa
Miharu Hirakawa
YKYusuke Kawamura
Yusuke Kawamura
HYHiromi Yatsuji
Hiromi Yatsuji
HKHiromitsu Kumada
Hiromitsu Kumada
Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG‐IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG‐IFN/ribavirin is not clear. The aims of this study were to investigate the predictive factors of sustained virological response to a 12‐week or 24‐week regimen of triple therapy in 72 of 81 Japanese adults infected with HCV genotype 1. Overall, sustained virological response and end‐of‐treatment response were achieved by 61% and 89%, respectively. Especially, the sustained virological response was achieved by 45% and 67% in the 12‐ and 24‐week regimens, respectively. Multivariate analysis identified rs8099917 near the IL28B gene (genotype TT) and substitution at aa 70 (Arg70) as significant determinants of sustained virological response. Prediction of response to therapy based on a combination of these factors had high sensitivity, specificity, and positive and negative predictive values. The efficacy of triple therapy was high in the patients with genotype TT, who accomplished sustained virological response (84%), irrespective of substitution of core aa 70. In the patients having genotype non‐TT, those of Arg70 gained high sustained virological response (50%), and sustained virological response (12%) was the worst in patients who possessed both genotype non‐TT and Gln70(His70). Conclusion: This study identified genetic variation near the IL28B gene and aa substitution of the core region as predictors of sustained virological response to a triple therapy of telaprevir/PEG‐IFN/ribavirin in Japanese patients infected with HCV genotype 1b. (HEPATOLOGY 2010)